Arrowhead begins dosing in Phase I/IIa trial for hyperlipidaemia

​Arrowhead Pharmaceuticals has dosed the first participants in its Phase I/IIa clinical trial of ARO-DIMER-PA, an investigational dual functional RNAi therapy, for mixed hyperlipidaemia.

The post Arrowhead begins dosing in Phase I/IIa trial for hyperlipidaemia appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.